AstraZeneca PLC (AZN.L)
| Previous close | 11,268.00 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,900,687 |
| Market cap | 175.981B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 36.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.28 (2.01%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Business Wire
Q1 2024 results
CAMBRIDGE, United Kingdom, April 25, 2024--Q1 Earnings Release (25 April 2024)
- Business Wire
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
- Business Wire
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
WILMINGTON, Del., April 11, 2024--AstraZeneca’s FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1
